Abiomed (Nasdaq:ABMD) - Stock Price, News & Analysis

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

ABMD Stock Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.

About the company

ABMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 13.08% per year

Earnings grew by 78.9% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 2.5% per year for the next 3 years

Volatile share price over the past 3 months

Large one-off items impacting financial results

Abiomed, Inc. Competitors

Insulet

NasdaqGS:PODD

US$11.6b

STERIS

NYSE:STE

US$20.1b

Teleflex

NYSE:TFX

US$9.7b

ResMed

NYSE:RMD

US$32.0b

Price History & Performance

Summary of all time highs, changes and price drops for Abiomed
Historical stock prices
Current Share Price	US$381.02
52 Week High	US$381.99
52 Week Low	US$219.85
Beta	1.4
1 Month Change	0.86%
3 Month Change	55.18%
1 Year Change	8.18%
3 Year Change	125.10%
5 Year Change	103.31%
Change since IPO	6,385.45%

Recent updates

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Jan 24

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

Jan 04

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Dec 14

Abiomed: Impella Will Continue To Drive Revenue Growth

Sep 10

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Sep 01

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Jul 13

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Jul 08

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Jun 08

Abiomed acquires preCARDIA a company targeting acute heart failure

Jun 01

Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today

May 16

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

May 06

Abiomed FQ4 2021 Earnings Preview

Apr 28

Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?

Apr 02

Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 12

Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?

Feb 18

Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Jan 31

Shareholder Returns

	ABMD	US Medical Equipment	US Market
7D	0.005%	2.1%	2.9%
1Y	8.2%	-1.9%	22.2%

Return vs Industry: ABMD exceeded the US Medical Equipment industry which returned -23.7% over the past year.

Return vs Market: ABMD exceeded the US Market which returned -22.8% over the past year.

Price Volatility

Is ABMD's price volatile compared to industry and market?
ABMD volatility
ABMD Average Weekly Movement	14.6%
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ABMD's share price has been volatile over the past 3 months.

Volatility Over Time: ABMD's weekly volatility has increased from 9% to 15% over the past year.

About the Company

Founded	Employees	CEO	Website
1981	2,003	Mike Minogue	www.abiomed.com

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Abiomed, Inc. Fundamentals Summary

How do Abiomed's earnings and revenue compare to its market cap?
ABMD fundamental statistics
Market cap	US$17.19b
Earnings (TTM)	US$266.76m
Revenue (TTM)	US$1.07b

64.4x

P/E Ratio

16.0x

P/S Ratio

Is ABMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABMD income statement (TTM)
Revenue	US$1.07b
Cost of Revenue	US$200.59m
Gross Profit	US$873.51m
Other Expenses	US$606.74m
Earnings	US$266.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	5.91
Gross Margin	81.32%
Net Profit Margin	24.84%
Debt/Equity Ratio	0%

How did ABMD perform over the long term?

See historical performance and comparison

This company has been acquired

ABMD Stock Overview

Rewards

Risk Analysis

Abiomed, Inc. Competitors

NasdaqGS:PODD

US$11.6b

NYSE:STE

US$20.1b

NYSE:TFX

US$9.7b

NYSE:RMD

US$32.0b

Price History & Performance

Recent News & Updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Is Abiomed (NASDAQ:ABMD) A Risky Investment?

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing

These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue